(ZURA)
0.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.00
0.00 (0.00%)
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
| Name | Position |
|---|---|
| Dr. Gary Whale Ph.D. | Chief Technology Officer |
| Dr. Kiran Nistala MBBS, Ph.D. | Chief Medical Officer & Head of Development |
| Dr. Sandeep C. Kulkarni M.D. | Co-Founder, CEO & Director |
| Dr. Someit Sidhu M.D. | Co-Founder & Director |
| Mr. Eric Hyllengren | Chief Financial Officer |
| Ms. Kimberly Ann Davis J.D. | COO, Chief Legal Officer & Corporate Secretary |
| Ms. Theresa Lowry | Chief Human Resources Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-19 | 8-K | tm269296d1_8k.htm |
| 2026-03-10 | 8-K | tm268344d1_8k.htm |
| 2026-03-05 | 8-K | tm268054d1_8k.htm |
| 2026-01-26 | 8-K | tm263758d1_8k.htm |
| 2026-01-12 | 8-K | tm262894d1_8k.htm |
| 2026-01-02 | 8-K | tm2531128d1_8k.htm |
| 2025-12-17 | 8-K | tm2533650d1_8k.htm |
| 2025-11-13 | 10-Q | zura-20250930x10q.htm |
| 2025-10-10 | 8-K | tm2528470d1_8k.htm |
| 2025-09-30 | 8-K | tm2527486d1_8k.htm |